NMDA受体与中枢神经系统退行性疾病

摘要/Abstract

摘要： 兴奋性氨基酸（excitatory amino acids, EAA）是存在于中枢神经系统的兴奋性神经递质，主要包括谷氨酸和天门冬氨酸。谷氨酸受体可分为离子型和代谢型两类。N-甲基-D-天冬氨酸（N-Methyl-D-Aspartate, NMDA）受体是离子型受体的一种亚型。NMDA受体可介导Ca2+内流，增强突触可塑性，参与学习记忆及神经系统发育。另一方面，机体兴奋性氨基酸剧增时，通过激动NMDA受体引起大量的Ca2+内流，细胞内Ca2+超载，进一步激活一系列胞内机制而导致细胞死亡。所以NMDA受体历来被认为是一把双刃剑。NMDA受体活性调节的失衡可能是神经退行性疾病、癫痫及缺血性脑损伤等许多中枢神经系统疾病发病的基础。本文重点就NMDA受体与神经退行性疾病的关系进行综述。

关键词: 兴奋性氨基酸, NMDA受体, 神经退行性疾病, 治疗

Abstract: Excitatory amino acids (EAA) are excitatory neurotransmitters in the central nervous system that mainly includes glutamic acid and asparaginic acid. There are two categories of glutamic acid receptors: ionic receptors and metabolic receptors. N-Methyl-D-Aspartate (NMDA) receptor is a subtype of ionic receptors. NMDA receptor mediates the calcium influx, promotes the synaptic plasticity, and participates in process of learning, memory and neurogenesis. On the other hand, excessive excitatory amino acids can excite NMDA receptor, and causes calcium influx, intracellular calciumoverload, further activates a series of intracellular mechanisms inducing the apoptosis. So NMDA receptor has been considered as a double-edged sword in central nervous system. The disturbance of activation regulation of NMDA receptors could be the basis of a plenty of central nervous system diseases including neurodegenerative diseases, epilepsy, ischemic cerebral injury, etc. This article reviews the relationship between NMDA receptors and neurodegenerative diseases.

Key words: excitatory amino acid, N-Methyl-D-Aspartate receptors, neurodegenerative diseases, therapy

张海红. NMDA受体与中枢神经系统退行性疾病[J]. 神经药理学报, 2015, 5(2): 17-23.

ZHANG Hai-hong. NMDA Receptor and Neurodegenerative Diseases in the Central Nervous System[J]. Acta Neuropharmacologica, 2015, 5(2): 17-23.

参考文献

[1]Vicini S, Wang J F, Li J H, et al. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors[J]. J Neurophysiol, 1998, 79(2): 555-566.

[2]王晓鹏, 黄永杰, 王芳, 等. NMDAR、NR2A、NR2B与糖尿病认知功能障碍的关系[J]. 南方医科大学学报, 2013, 33(12): 1848-1851.

[3]Madry Christian, Mesic Ivana, Bartholomäus Ingo, et al. Principal role of NR3subunits in NR1/NR3 excitatory glycine receptor function [J]. Biochem Biophys Res Commun, 2007, 354(1): 102-108.

[4]陈松芳, 黄汉津, 王小同. NMDA受体NR1亚单位与学习记忆[J].中国行为医学科学, 2006, 15(1): 91.

[5]Chung H J, Huang Y H, Lau L F, et al. Regulation of NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand [J]. J Neuroscience, 2004, 24(45): 10248-10259.

[6]Bliss T V. Young receptors make smart mice [J]. Nature, 1999, 401(6748):25-27.

[7]Goebel D J, Poosch M S. NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A [J]. Brain Res Mol Brain Res, 1999, 69(2): 164-170.

[8]Kuriyama I, Asano N, Kato I, et al. Dipeptide alcohol-based inhibitors of eukaryotic DNA polymerase alpha [J]. Bioorg Med Chem, 2005, 13(6): 2187-2196.

[9]杨宝峰. 药理学(第八版)[M]. 北京: 人民卫生出版社, 2013: 110-125.

[10]楚世峰, 陈乃宏. 突触内外NMDA 受体的分布调控及其生物学功能[J]. 神经药理学报, 2011, 1(5): 40-48.

[11]王传功, 徐霞, 库宝善. NMDA 受体与帕金森氏病[J]. 济宁医学院学报, 2000, 23(2) :75-76.

[12] Abekawa Tomohiro, Ohmori Tetsuro, Ito Kouichi, et al. D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex[J]. Brain Res, 2000, 867(1-2): 250-254.

[13]王爽, 高捷, 苏兴利, 等. 帕金森病模型大鼠内侧前额叶皮层锥体神经元NMDA受体敏感性下降[J].中国现代医学杂, 2014, 24 (1): 1-4.

[14] Faucard Raphael, Armand Vincent, Heron Anne, et al. N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain[J]. J Neurochem, 2006, 98(5):1487-1496.

[15]Jones Susan, Alasdair J Gibb. Functional NR2B-and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones[J]. J Physiol, 2005, 569(Pt1): 209-221.

[16]杨辉, 张可成, 蔡文琴. PD 鼠纹状体内NMDA受体密度及黑质内NMDA受体mRNA含量的观察[J]. 第三军医大报, 1996, 18(3): 206-208.

[17] Armentero Marie-Therese, Fancellu Roberto, Nappi Giuseppe, et al. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson’s disease[J]. Neurobiol Dis, 2006, 22(1): 1-9.

[18]Turle-Lorenzo Nathalie, Breysse Nathalie, Baunez Christelle, et al. Functional interaction Between mGlu5 and NMDA receptors in a rat model of Parkinson’s disease[J]. Psychopharmacology(Berl), 2005, 179(1): 117 -127.

[19]王传功, 王旭, 齐汝霞. NMDA和GABA受体拮抗剂对帕金森模型小鼠神经细胞的影响[J]. 济宁医学院学报, 2006, 29(2):20-21.　

[20]王传功, 徐霞, 库宝善. NMDA受体和GABA受体拮抗剂对小鼠帕金森模型的行为药理学影响[J].中国行为医学科学, 1998, 7(1): 19-21.

[21]王传功, 徐霞, 辛勤, 等. NMDA 受体拮抗剂和GABA 受体拮抗剂对小鼠帕金森模型的影响[J]. 济宁医学院学报, 1998, 21(3): 8-10.　

[22]Steece-Collier K, Chambers L K, Jaw-Tsai S S, et al. Antiparkinsonian actions of CP101, 606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors [J]. Exp Neurol, 2000, 163(1):239-243.

[23]张奇. 铅暴露AD模型大鼠脑不同区域NMDA受体亚基(NR1、NR2A、NR2B)表达的研究[D]. 江苏：中国药科大学, 2007, 1-20.

[24]Behe P, Stern PWyllie D J, Nassar M, et al. Determination of NMDA NR1 subunit copy number in recombinant NMDA receptors[J]. Proc Biol Sci, 1995, 262(1364): 205-213.

[25]Mony Laetitia, Kew James N C, Martin J Gunthorpe, et al. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential[J]. Br J Pharmacol, 2009, 157(8): 1301-1317.

[26] Bi Hong, Sze Chun-I. N-methyl-d-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer' s disease[J]. Neurological Sciences, 2002, 200(1-2):11-18

[27]刘志安, 赵娓娓, 吕春娥, 等. AD样大鼠海马NMDAR亚单位2B和2A的表达及其与细胞凋亡的关系[J]. 山东大学学报(医学版), 2011, 49(2): 14-18.

[28] Shirley W Y Tsanq, Harry V Vinters, Jeffrey L Cumminqs, et al. Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer’s disease[J]. Neurobiol Aging, 2008, 29(10): 1524-1532.

[29]吴婷, 丁新生, 董海蓉, 等. NMDA受体拮抗剂对Aβ42基因果蝇阿尔茨海默病模型的神经保护作用[C]. 全国抗衰老与老年痴呆学术会议论文汇编, 2009: 37.

[30]曹续政, 张黎明, 沈月娥, 等. NMDA受体介导了加兰他敏对阿尔茨海默病大鼠认知功能的改善[J]. 中风与神经疾病杂志, 2006, 23(6): 678-680.

[31]李玺, 袁海峰, 张智燕. 脑尔康对AD 模型小鼠脑内NMDA受体亚单位NR2B表达的影响[J]. 中国医药学报, 2004, 19(1): 11-14.

[32]李玺, 刘颖, 张欣, 等. 人参皂苷Rg1对大鼠脑片AD模型磷酸化Tau蛋白及NMDA受体亚单位NR1, NR2B表达的影响[J]. 中国中药杂志, 2010, 35(24): 3339-3343.

[33] Alice Wexler． Stigma, history, and Huntington' s disease[J]．Lancet, 2010, 376(9734): 18-19.

[34]沈原．亨廷顿病发病机制的研究进展[J]．国际神经病学神经外科学杂志, 2010, 37(1) : 70-72.

[35]Warby S C, Montpetit AHayden A R, Carrol J B, et al． CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup[J]．Am J Hum Genet, 2009, 84(3): 351-366.

[36]袁维秀, 杨红菊. N-甲基-D-天冬氨酸-2B 受体功能的研究进展[J]. 国外医学药学分册, 2004, 31(3): 146-149.

[37]Hodgson J Graeme, Agopyan Nadia, Gutekunst Claire-Anne, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytop lasmic toxicity, and selective striatal neurodegeneration[J]. Neuron, 1999, 23(1):181-192.

[38]Sammels Eva, Parys Jan B, Missiaen Luding, et al．Intracellular Ca2+ storage in health and disease: A dynamic equilibrium[J]. Cell Calcium, 2010, 47(4): 297-314.

[39]Lau A, Tymianski M. Excitotoxicity [M]. Oxford: Pergamon Press, 2010: 515-535.

[40] Shehadeh Jacqueline, Fernandes Herman B, Zeron Mullins Melinda M, et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease[J]. Neurobiol Dis,2006,21(2) : 392-403.

[41]Olney J W. New insights and new issues in developmental neuro toxicology[J]. Neurotoxicology, 2002, 23(6):659-668.

[42] Verhagen M L, Morris M J, Farmer C, et al．Huntington's disease: A randomized,controlled trial using the NMDA antagonist amantadine [J]. Neurology, 2002, 59 (5): 694-699.

[43]Mary V, Wahl F, Stutzmann J M. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission [J]. Neurosci Lett, 1995, 201(1): 92-96.

[44]Schiefer Johannes, Landwehrmeyer G Bernhard, Lüesse Hans-Gerd, et al．Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington' s disease[J]．Mov Disord, 2002, 17(4): 748-757.

[45]Seppi Klaus, Mueller Joerg, Bodner Thomas, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up [J]. J Neurol, 2001, 248(10):866-869.

[46]李晓光, 崔丽英. 肌萎缩侧索硬化的现代治疗[J]. 中国现代医药杂志, 2013,15(11): 97-101.

[47] Zhi Qi-xiong, McNamara James O. Fas(t) balls and Lou Gehrig disease. A clue to selective vulnerability of motor neurons? [J]. Neuron, 2002, 35(6):1011-1013.

[48] von Lewinski Friederike, Keller BernhardU. Ca2 +, mitochondria and selective motoneuron vulnerability: implications for ALS [J]. Trends Neurosci, 2005, 28(9):494 -500.

[49]郑梅, 樊东升. NMDA受体不同亚单位分布造成肌萎缩侧索硬化中运动神经元选择性易损[J]. 北京大学学报(医学版), 2011, 43(2): 228-233.

[50]Miller R G, Mitchell J D, Lyon M．Riluzole for amyotrophic lateral sclerosis ( ALS ) / motor neuron disease ( MND )[J]．Cochrane Database Syst Rev,2012, 3: CD0 01447．

[51]Lee C T, Chiu Y W, Wang K C, et al．Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan[J]. J Epidemiol, 2013, 23(1): 35-40.